CD274 and neoplasm: In immunocompetent mouse models of renal adenocarcinoma and melanoma, TIL therapy using mesenchymal stem cells (MSCs) infected with oncolytic adenovirus dlE102 significantly reduced tumor volume by 50% and increased TILs, while decreasing their PD-1 + subsets demonstrates that PD-1-selected tumor-infiltrating lymphocytes (TILs) effectively recognize and target tumor cells in vivo, showing significant antitumor activity in mouse models of solid tumors and multiple myeloma, with enhanced efficacy through PDL-1 blockade [86].